AC   CVCL_3866
DR   CLO; CLO_0050885
DR   BioSample; SAMN03472264
DR   Cosmic; 713497
DR   Cosmic; 735333
DR   Cosmic; 1177619
DR   Cosmic; 1223488
DR   Cosmic; 1241346
DR   Cosmic; 1622898
DR   Cosmic; 1696758
DR   Cosmic; 2030474
DR   DepMap; ACH-002026
DR   IARC_TP53; 2377
DR   RCB; RCB0658
DR   TOKU-E; 4122
DR   Wikidata; Q54887500
RX   PubMed=2429643;
RX   PubMed=2448191;
RX   PubMed=6532401;
RX   PubMed=6706228;
RX   PubMed=8105795;
RX   PubMed=9436037;
RX   PubMed=9573483;
RX   PubMed=10457904;
RX   PubMed=15901131;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Doubling time: 34 hours (at 5th passage), 30 hours (at 15th passage) (PubMed=6706228); 30 hours (PubMed=6532401); 28 hours (PubMed=10457904).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala138Val (c.413C>T); ClinVar=VCV000184863; Zygosity=Unspecified (PubMed=8105795).
CC   Derived from sampling site: Endometrium.
ST   Source(s): DepMap; RCB
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 8,11
ST   D16S539: 10,12
ST   D18S51: 12,18,19
ST   D21S11: 29,30
ST   D3S1358: 14,15
ST   D5S818: 9,12,13,14 (DepMap)
ST   D5S818: 9,13,14 (RCB)
ST   D7S820: 10,13 (RCB)
ST   D7S820: 10,13,14 (DepMap)
ST   D8S1179: 11,13
ST   FGA: 21,22
ST   Penta D: 8,11
ST   Penta E: 11,13
ST   TH01: 6,7
ST   TPOX: 8,9
ST   vWA: 17,18,19 (RCB)
ST   vWA: 17,19,20,21 (DepMap)
DI   NCIt; C7359; Endometrial adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 23-06-22; Version: 21
RX   PubMed=2429643; DOI=10.1111/j.1447-0756.1986.tb00192.x;
RA   Ishiwata I., Ishiwata C., Nozawa S., Ishikawa H.;
RT   "CA125 production by gynecologic tumors in vitro and its modulation
RT   induced by dibutyl cyclic adenosine monophosphate.";
RL   Asia Oceania J. Obstet. Gynaecol. 12:285-290(1986).
RX   PubMed=2448191; DOI=10.1016/0090-8258(88)90151-5;
RA   Ishiwata I., Ishiwata C., Soma M., Ono I., Nakaguchi T., Ishikawa H.;
RT   "Tumor angiogenic activity of gynecologic tumor cell lines on the
RT   chorioallantoic membrane.";
RL   Gynecol. Oncol. 29:87-93(1988).
RX   PubMed=6532401; DOI=10.1111/j.1447-0756.1984.tb00721.x;
RA   Ishiwata I., Ishiwata C., Ishikawa H.;
RT   "Effects of estradiol-17 beta and progesterone on cell proliferation
RT   and differentiation of the human endometrial carcinoma cell line
RT   (HHUA) in vitro.";
RL   Asia Oceania J. Obstet. Gynaecol. 10:531-538(1984).
RX   PubMed=6706228; DOI=10.1016/0090-8258(84)90212-9;
RA   Ishiwata I., Ishiwata C., Soma M., Arai J., Ishikawa H.;
RT   "Establishment of human endometrial adenocarcinoma cell line
RT   containing estradiol-17 beta and progesterone receptors.";
RL   Gynecol. Oncol. 17:281-290(1984).
RX   PubMed=8105795; DOI=10.1002/mc.2940080303;
RA   Enomoto T., Fujita M., Inoue M., Nakazawa-Miyamoto A., Tanizawa O.,
RA   Nomura T.;
RT   "Alterations of the Rb gene and its association with Ki-ras activation
RT   and p53 inactivation in endometrial adenocarcinoma.";
RL   Mol. Carcinog. 8:132-137(1993).
RX   PubMed=9436037;
RA   Soma M., Ishiwata I., Ishiwata C., Nakaguchi T., Ono I., Kiguchi K.,
RA   Hashimoto H., Tachibana T., Ishikawa H., Nozawa S.;
RT   "Tissue reconstruction of gynecologic tumor cells in the rotation
RT   culture system.";
RL   Hum. Cell 10:175-181(1997).
RX   PubMed=9573483;
RA   Ishiwata I., Tokieda Y., Ishiwata C., Okane N., Iguchi M., Sato K.,
RA   Ishikawa H.;
RT   "Effects of feeder cells (human cancer cell lines) on the development
RT   of mouse embryos by co-culture.";
RL   Hum. Cell 10:237-246(1997).
RX   PubMed=10457904;
RA   Ishiwata I., Sudo T., Kiguchi K., Ishikawa H.;
RT   "Tumor angiogenesis factors produced by cancer cells.";
RL   Hum. Cell 12:37-46(1999).
RX   PubMed=15901131; DOI=10.1016/j.prp.2005.01.002;
RA   Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.;
RT   "Correlation between DNA alterations and p53 and p16 protein
RT   expression in cancer cell lines.";
RL   Pathol. Res. Pract. 201:109-115(2005).